What laboratory tests should be obtained for a newborn of a mother taking levothyroxine (Synthroid)?

Laboratory Testing for Newborns of Mothers on Levothyroxine (Synthroid)

For newborns of mothers taking levothyroxine for hypothyroidism alone (without autoimmune thyroid disease or TSH-receptor antibodies), routine newborn screening is sufficient—no additional thyroid function testing is required beyond the standard screening program.

Clinical Context and Evidence

The question specifically addresses newborns of mothers on Synthroid (levothyroxine), which indicates maternal hypothyroidism treatment. This is fundamentally different from maternal Graves' disease or other autoimmune thyroid conditions.

Standard Newborn Screening Applies

All newborns should undergo routine newborn screening for congenital hypothyroidism, which is the most sensitive method for detecting primary hypothyroidism 1. The screening typically measures TSH (most sensitive for primary hypothyroidism) and may include T4 depending on the program 1.

Key timing considerations:

• Initial screening should occur after 24 hours of life when possible 1
• If collected within the first 24 hours, repeat screening at approximately 2 weeks of age should be considered 1

No Additional Testing Needed for Maternal Levothyroxine Alone

Multiple high-quality studies demonstrate that additional thyroid function testing at 10-14 days of life in newborns of mothers with hypothyroidism provides no clinical benefit beyond standard newborn screening:

• A 2021 study of 1,392 newborns found that all 8 cases of congenital hypothyroidism were detected by newborn screening; serum thyroid function tests at 2 weeks added no additional cases 2
• A 2016 study of 319 patients found only 2 cases of congenital hypothyroidism, both detected by newborn screening; the day 10-14 testing detected zero additional cases 3

The evidence clearly shows that routine thyroid function testing at 2 weeks of age should be discontinued in this population due to the robust nature of existing newborn screening programs 3.

Important Clinical Distinctions

When Additional Testing IS Required

The situation differs entirely if the mother has:

Graves' disease or TSH-receptor antibodies - This requires comprehensive neonatal assessment 4:

• Umbilical cord blood testing at delivery: TSH, free T4, and anti-TSH-receptor antibodies 4
• Anti-TSH-R antibodies >2 IU/L (or >5-6.8 IU/L depending on assay) identify neonates at risk for hyperthyroidism 4
• Follow-up testing at 3-5 days of life: Rapid increase in free T4 beyond age-related upper limits predicts neonatal hyperthyroidism 4
• Continued monitoring with pediatric endocrinology if antibodies are elevated 4

Maternal antithyroid drug use - Even without Graves' disease, if the mother was on antithyroid medications, umbilical cord testing is indicated 4.

Special Populations Requiring Repeat Screening

Regardless of maternal thyroid status, certain high-risk neonates should have repeat screening at approximately 2 weeks of age 1:

• Preterm infants (gestational age <37 weeks)
• Low birth weight and very low birth weight infants
• Critically ill neonates admitted to NICU
• Multiple births, particularly same-sex twins
• Any specimen collected within the first 24 hours of life

Common Pitfalls to Avoid

1. Do not confuse maternal hypothyroidism on levothyroxine with maternal Graves' disease - These require completely different neonatal testing approaches
2. Do not order routine 2-week thyroid function tests in healthy term newborns of mothers with simple hypothyroidism—this adds no clinical value and increases unnecessary testing 2, 3
3. Do not rely solely on umbilical cord thyroid hormone levels to predict neonatal thyroid dysfunction—these reflect fetal status, not postnatal function 4
4. Remember that TSH normally fluctuates significantly in the first days of life, with physiologic elevation in the first 24-48 hours 1

Practical Algorithm

For a newborn of a mother on Synthroid for hypothyroidism:

1. Confirm maternal diagnosis is simple hypothyroidism (not Graves' disease, no TSH-receptor antibodies)
2. Ensure standard newborn screening is performed (ideally after 24 hours of life)
3. If screening collected <24 hours or infant is preterm/low birth weight/critically ill/multiple birth → arrange repeat screening at 2 weeks
4. If newborn screening is abnormal → obtain confirmatory venous TSH and free T4 immediately 1
5. No additional testing needed if screening is normal and infant is term, healthy, and screening was done >24 hours of life

The FDA label for Synthroid confirms that thyroid hormones cross the placenta minimally (cord blood levels approximately one-third of maternal levels), and transfer may not prevent in utero hypothyroidism 5. However, this relates to fetal thyroid development, not postnatal testing requirements, which are adequately addressed by newborn screening programs.